Sygnature
Discovery is a leading United Kingdom-based provider of integrated drug
discovery services. Key areas of
expertise include medicinal and synthetic chemistry, computational chemistry
and bioscience (in vitro biology and
screening). The company was founded in
2004 in BioCity (www.biocity.co.uk ) and occupies modern, purpose-built
laboratories and offices near to the centre of Nottingham. Our clients are located in the USA and Europe,
and range from small biotechnology companies to medium-sized pharmaceutical
companies.
Sygnatures team of over 50 industry-experienced medicinal chemists
and bioscientists add considerable value to clients drug discovery activities
by undertaking complete drug discovery programmes and key elements of the drug
discovery process, such as hit finding, hit-to-lead and lead optimisation. Sygnatures scientists provide considerable
intellectual input into clients projects; thereby generating novel
intellectual property. Pharmaceutical
candidates discovered at Sygnature for clients are currently undergoing
clinical trials in a variety of diseases with unmet medical need.
Follow Sygnature Discovery on:
This page was last updated on Wednesday, 14 September 2011
